Tarlatamab in Combination Therapy: Future Potential for SCLC

Author(s):

Panelists discuss how tarlatamab could serve as a promising combination therapy for previously treated small cell lung cancer, highlighting its potential clinical benefits when paired with durvalumab as maintenance therapy after standard regimens, and emphasizing the importance of statistically significant trial end points to encourage its adoption in community oncology practices.

EP: 1.Current Landscape of First-Line Treatment for Limited-Stage SCLC: Diagnostic Workup & Multidisciplinary Approaches

EP: 2.Surgical and Radiotherapy Choices in Limited-Stage SCLC

EP: 3.Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcomes and Implications

EP: 4.Immunotherapy in Limited-Stage SCLC

EP: 5.Defining Platinum Sensitivity in SCLC

EP: 6.Changing Standard of Care: Potential of Tarlatamab in SCLC Treatment

EP: 7.Adverse Event Management: CRS and ICANS with Tarlatamab

Now Viewing

EP: 8.Tarlatamab in Combination Therapy: Future Potential for SCLC

EP: 9.Ifinatamab Deruxtecan and B7-H3 in SCLC

EP: 10.Comparing Treatment Schedules: Ifinatamab Deruxtecan vs Amrubicin, Topotecan, and Lurbinectedin in SCLC

EP: 11.Insights from ARTEMIS-001

EP: 12.Targeted Therapies and Biomarkers for SCLC: What’s Next on the Horizon

Video content above is prompted by the following:

8. Dr Leal: In your opinion, what is the future treatment potential of tarlatamab as combination therapy with other anticancer agents for previously treated small cell lung cancer (SCLC) that has advanced after 2 or more lines of prior therapy?

9. Dr Sen: What further clinical benefits might we anticipate for patients with extensive-stage SCLC by adding tarlatamab to durvalumab as maintenance therapy after primary treatment with platinum-based chemotherapy+etoposide+durvalumab?

What statistically significant trial end points might persuade community oncologists to consider dual maintenance with a bispecific T-cell engager and a PD-L1 inhibitor?